Inhibition of a K9/K36 demethylase by an H3.3 point mutation found in paediatric glioblastoma.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30087349.
- Also identified by DOI 10.1038/s41467-018-05607-5 and PMC identifier 6081460.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
An array of oncogenic histone point mutations have been identified across a number of different cancer studies. It has been suggested that some of these mutant histones can exert their effects by inhibiting epigenetic writers. Here, we report that the H3.3 G34R (glycine to arginine) substitution mutation, found in paediatric gliomas, causes widespread changes in H3K9me3 and H3K36me3 by interfering with the KDM4 family of K9/K36 demethylases. Expression of a targeted single-copy of H3.3 G34R at endogenous levels induced chromatin alterations that were comparable to a KDM4 A/B/C triple-knockout. We find that H3.3 G34R preferentially binds KDM4 while simultaneously inhibiting its enzymatic activity, demonstrating that histone mutations can act through inhibition of epigenetic erasers. These results suggest that histone point mutations can exert their effects through interactions with a range of epigenetic readers, writers and erasers.
Medical subject headings
- Brain Neoplasms
- Chromatin
- Glioblastoma
- Histones
- Mutation
- Point Mutation